Trevi Therapeutics (TRVI) Stock May Be Overvalued Despite Its 5 Year Surge

Trevi Therapeutics stock has delivered a very large 5 year return, yet the current valuation checks lean expensive rather than cheap, which raises the question of how much of that strength is already reflected in the price.

• Over the past 5 years, Trevi Therapeutics has returned about 7.6x, which sets a high bar for any further upside to be justified by fundamentals.
• Future progress in turning its drug pipeline into consistent revenue can support the current share price. The risk is that funding needs or clinical setbacks weigh on how investors price that growth.
• On Simply Wall St's broader valuation checks, Trevi Therapeutics scores 1 out of 6, suggesting the stock does not screen as a clear bargain on most measures.

The issue now is whether Trevi Therapeutics' current price still offers an attractive entry point after such a strong multi year run, or whether expectations have already moved too far ahead of the business.

Trevi Therapeutics delivered 153.8% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Is Trevi Therapeutics Getting Expensive on Book Value?

The P/B ratio is often a useful cross check for a business like Trevi Therapeutics that is still working to convert its pipeline into revenue. Trevi’s P/B of 14.3x sits far above both the broader Pharmaceuticals industry average of 2.4x and the peer group average of 5.3x.

This wide premium suggests investors are paying a high price relative to the company’s net assets, especially compared with other drug developers. The model heavily penalises Trevi Therapeutics for its current losses and risk profile, so the implied “fair” multiple comes out extremely low. This is better read as a warning signal than a precise target. Taken together, the current P/B indicates that a lot of optimism is already embedded in the stock compared with typical sector valuations.

On this P/B yardstick, Trevi Therapeutics stock screens as clearly overvalued versus both its industry and peer benchmarks.

See what the numbers say about this price — find out in our valuation breakdown.

The Trevi Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Trevi Therapeutics pick up where the valuation puzzle leaves off by spelling out which paths for Trevi Therapeutics' growth, margins and earnings would need to play out for the stock to look materially stronger or weaker than today's price on the Community page. Each scenario links its number to a clear view on how the business might scale, what profitability could look like and how key risks might evolve over time, so you can revisit those assumptions as new information emerges.

One of the top community narratives on Trevi Therapeutics: 27% undervalued

"Parallel development of multiple chronic cough indications, including refractory chronic cough with a Phase IIb dose ranging trial, creates several potential data readouts from the same core asset…"

Read one of the top narratives on Trevi Therapeutics

Do you think there's more to the story for Trevi Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Trevi Therapeutics, the market multiple checks point to an overvalued stock, with a sizeable gap between its current P/B and sector norms. That premium may make sense only if the company turns its pipeline into meaningful, durable revenue without heavy dilution or prolonged setbacks. The key debate from here is whether future clinical and commercial progress will be strong enough to sustain, or eventually justify, the valuation investors are already paying today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com